Similar articles

• Mucosal suppression by oral pre-treatment with ovalbumin and its conversion into stimulation when ovalbumin was conjugated to cholera toxin or its B subunit.

  van der Heijden PJ, Stok W, Bianchi AT. van der Heijden PJ, et al. Adv Exp Med Biol. 1995;371B:1251-5. Adv Exp Med Biol. 1995. PMID: 7502794 No abstract available.
• Effect of cholera toxin and its B subunit on intestinal permeability for ovalbumin.

  Pierre PG, Mbella EG, Vaerman JP. Pierre PG, et al. Adv Exp Med Biol. 1995;371B:1519-21. Adv Exp Med Biol. 1995. PMID: 7502848 No abstract available.
• Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.

  Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Porgador A, et al. J Immunol. 1997 Jan 15;158(2):834-41. J Immunol. 1997. PMID: 8993001
• Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.

  Sun JB, Czerkinsky C, Holmgren J. Sun JB, et al. Scand J Immunol. 2010 Jan;71(1):1-11. doi: 10.1111/j.1365-3083.2009.02321.x. Scand J Immunol. 2010. PMID: 20017804 Review.
• Cholera toxin and its subunits as potential oral adjuvants.

  Elson CO. Elson CO. Curr Top Microbiol Immunol. 1989;146:29-33. doi: 10.1007/978-3-642-74529-4_3. Curr Top Microbiol Immunol. 1989. PMID: 2659272 Review.